State Street Corp Neoleukin Therapeutics, Inc. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.25 $426,025 - $1.04 Million	-463,071 Reduced 79.07%	122,556 $126,000
Q1 2022 May 16, 2022	BUY	$1.72 - $5.23 $9,719 - $29,554	5,651 Added 0.97%	585,627 $1.1 Million
Q4 2021 Feb 14, 2022	SELL	$4.65 - $7.75 $141,583 - $235,972	-30,448 Reduced 4.99%	579,976 $2.8 Million
Q3 2021 Nov 15, 2021	SELL	$6.05 - $9.66 $3.78 Million - $6.03 Million	-624,674 Reduced 50.58%	610,424 $4.41 Million
Q2 2021 Aug 16, 2021	SELL	$9.23 - $13.12 $3.17 Million - $4.51 Million	-343,970 Reduced 21.78%	1,235,098 $11.4 Million
Q1 2021 May 17, 2021	BUY	$11.26 - $15.78 $4.52 Million - $6.34 Million	401,718 Added 34.12%	1,579,068 $19.4 Million
Q4 2020 Feb 16, 2021	BUY	$10.17 - $14.56 $6.31 Million - $9.04 Million	620,773 Added 111.53%	1,177,350 $16.6 Million
Q3 2020 Nov 10, 2020	BUY	$9.68 - $17.01 $478,550 - $840,923	49,437 Added 9.75%	556,577 $6.68 Million
Q2 2020 Aug 14, 2020	BUY	$9.95 - $17.05 $4.91 Million - $8.41 Million	493,387 Added 3587.49%	507,140 $8.42 Million
Q1 2020 May 11, 2020	BUY	$6.12 - $13.64 $84,168 - $187,590	13,753 New	13,753 $157,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.